프레사토비르
Presatovir![]() | |
임상자료 | |
---|---|
상명 | 프레사토비르 |
법적현황 | |
법적현황 |
|
식별자 | |
| |
CAS 번호 | |
펍켐 CID | |
유니 | |
화학 및 물리적 데이터 | |
공식 | C24H30CLN7O3S |
어금질량 | 532.1 g·192−1 |
3D 모델(JSmol) | |
| |
|
프레사토비르(GS-5806)는 호흡기세포융합바이러스 치료제로 개발된 항바이러스제다.[1][2]융해 억제제 역할을 하며, 임상 2상에서도 유망한 결과를 보여 왔다.[3][4]
참고 항목
참조
- ^ Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, et al. (February 2015). "Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study". Journal of Medicinal Chemistry. 58 (4): 1630–1643. doi:10.1021/jm5017768. PMID 25574686.
- ^ Yamaguchi-Sasaki T, Tamura Y, Ogata Y, Kawaguchi T, Kurosaka J, Sugaya Y, et al. (2020). "Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors". Chemical & Pharmaceutical Bulletin. 68 (4): 345–362. doi:10.1248/cpb.c19-00895. PMID 32238652.
- ^ Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, et al. (December 2019). "A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract". Clinical Infectious Diseases. doi:10.1093/cid/ciz1167. PMID 31915807.
- ^ Stray K, Perron M, Porter DP, Anderson F, Lewis SA, Perry J, et al. (January 2020). "Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus". The Journal of Infectious Diseases. doi:10.1093/infdis/jiaa028. PMID 31971597.